Valuation : Novacyt

Market Cap 36.98M 43.01M 34.79M 31.75M 59.24M 4.08B 59.55M 412M 159M 2.08B 161M 158M 6.63B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 38.93M 45.28M 36.63M 33.43M 62.38M 4.29B 62.7M 434M 168M 2.19B 170M 166M 6.98B EV / Sales 2026 *
1.28x
EV / Sales 2027 * 1.2x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+3.66%
1 week+1.59%
Current month+1.59%
1 month+15.91%
3 months+10.87%
6 months+32.64%
Current year+30.43%
1 week 0.48
Extreme 0.4815
0.54
1 month 0.43
Extreme 0.43
0.57
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
30/03/26 Buy

Chief Executive Officer

1,792 0.0025%
30/03/26 Buy

Chairman

15,228 0.0216%
30/03/26 Buy

Chairman

56,732 0.0803%
Change 5-day change 1-year change 3-year change Capi.($)
+3.66%+1.59%+12.83%-41.48% 41.48M
-7.12%+75.58% - - 1.56B
+2.19%+3.32%-34.87%-41.18% 666M
+2.03%+1.10%+66.57% - 349M
-2.38%-5.74%-43.76%-37.59% 128M
0.00%-9.18%-31.27%+17.11% 69.03M
Average -0.27%+13.83%-6.10%-25.79% 469.09M
Weighted average by Cap. -3.23%+50.22%-5.77%-36.24%

Financials

2026 *2027 *
Net sales 30.52M 35.5M 28.72M 26.21M 48.91M 3.37B 49.16M 340M 132M 1.72B 133M 130M 5.47B 34.86M 40.55M 32.8M 29.93M 55.85M 3.84B 56.14M 389M 150M 1.96B 152M 149M 6.25B
Net income - -
Net Debt 1.96M 2.27M 1.84M 1.68M 3.13M 216M 3.15M 21.8M 8.44M 110M 8.54M 8.36M 351M 4.84M 5.63M 4.56M 4.16M 7.76M 534M 7.8M 53.97M 20.88M 273M 21.15M 20.69M 868M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
08/09/26 0.5100 +3.66% 873,465
07/09/26 €0.4920 -3.34% 311,920
04/09/26 €0.5090 +0.59% 157,240
03/09/26 €0.5060 -1.17% 85,537
02/09/26 €0.5120 -3.76% 211,707

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!